Pre-existing anti-RhD-alloantibodies in allogeneic bone marrow donors are relatively seldom observed and may lead to hemolytic post transplant complications in RhDmismatched recipients. We describe an HLA-matched sibling bone marrow transplant with RhD-mismatch and presence of pre-formed anti-RhD-alloantibodies in the donor. The recipient was a 58-year-old RhD-positive female with AML M2 FAB morphology, 46XX, FLT3( þ ), diagnosed 9 months before, in CR1 achieved after two induction chemotherapy courses, then followed by two consolidation chemotherapy courses and maintenance therapy. The donor was her HLA-matched 57-year-old RhD-negative sister who had been pregnant in the past and who tested anti-RhD-antibody positive in titer 1 (and antiRhC-antibody in titer 32). ABO was compatible in donor and recipient.
Myeloablative conditioning consisted of Treosulfan 14 g/ m 2 /day on days from À6 to À4, Fludarabine 30 mg/m 2 /day on days from À6 to À2. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine-A 3 mg/kg/day and methotrexate 15 mg/m 2 on day þ 1 and 10 mg/m 2 on days þ 3, þ 6 and þ 11. Transplanted bone marrow after centrifugation and removal of anti-RhD-antibodies positive plasma contained 3.0 Â 10 8 NC/kg, 3.0 Â 10 6 CD34 þ cells/kg and 35.0 Â 10 6 CD3 þ cells/kg. No toxicity related to conditioning was observed. Myeloablation was complete with 16 days of agranulocytosis o0.5 G/l, including 11 days of absolute agranulocytosis o0.1 G/l. No serious complications were observed during the post transplant aplasia, which was followed by complete recovery: an absolute granulocyte count of 1.0 G/l was achieved on day þ 21, platelets were 50 G/l on day þ 23, reticulocytes 10 promille on day þ 19. Filtered irradiated A RhD-negative erythrocytes were transfused twice and single-donor platelets thrice. No acute GVHD was observed. Presence of recipient-type RhD-antigen, absence of allo-reactive antibodies directed against erythrocytes and normal bilirubin were documented up to day þ 20. This was followed by merging symptoms of hemolysis starting from day þ 23 (decrease in Hb from 10.2 g% on day þ 22 to 7.1 g% on day þ 26; bilirubin 2.5 mg%; LDH 542 U/l (normal range 91-180 U/l); haptoglobin 0.065 g/l; reticulocytes 59 promille). Short-course of methylprednisolone at low dose was administered, and washed filtered irradiated A RhD-negative erythrocytes were transfused twice. The presence of class IgG alloreactive anti-RhD-antibodies in titer 2 (and trace of antiRhC-antibodies) and donor-type lack of RhD-antigen were detected on day þ 26. Symptoms of hemolysis abated within the next few days. Full 100% donor chimerism (YNZ polymorphism) was confirmed on day þ 27. Currently the patient is doing well with normal peripheral blood morphology and no symptoms of hemolysis under ambulatory control.
It has been demonstrated recently that RhD-mismatch may result in poorer survival of BMT recipients. 1 Engraftment from RhD-negative donor to RhD-positive recipient is observed in approximately 10% of ABOcompatible transplants. 2 Although at the time of RhD-mismatched transplantation primary immunization may occur, usually anti-RhD-antibodies are not produced post transplant, unless additional factors such as exposure to RhD-positive blood products after the transplant, post transplant RhD-positive pregnancy or prolonged immunosuppression owing to GVHD and stimulated antibody production. [3] [4] [5] In contrast, when pre-formed anti-RhD-antibodies are detectable in an RhD-negative donor, severe anti-RhDmediated hemolytic anemia may occur post transplant owing to the passage of donor lymphocytes with immunologic information, as has been reported by several investigators in solid organ recipients. The formation of anti-RhD-antibodies led to hemolysis between the 8th and 40th post transplant days and was directly related to the amount of lymphocytes transfused with the transplanted organ.
2,6-8 Similar observations are missing in hematopoietic cell recipients.
Also RhD-negative recipients of RhD-positive donors of haemopoietic cells or solid-organs seldom develop antiRhD-antibodies. 4 In contrast, in the case of pre-existing recipient-derived allo-antibodies directed against donor RBC antigens, delayed hemolysis may be observed. When chimerism is evident, the remaining recipient marrow may still produce anti-RhD-antibodies. 9 Even when peripheral circulating B cells are solely of donor origin, hemolysis may be mediated by long-term production of antibodies by long-living recipient plasma cells, which survive the conditioning regimen, as was observed from 1-20 months after allogeneic BMT. 10 We conclude that patients with RhD-mismatch transplanted from donors with pre-existing anti-RhDalloantibodies may quickly eliminate recipient-type erythrocytes and should be carefully followed-up for 
